254 related articles for article (PubMed ID: 22045098)
1. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.
Lai KN; Lam MF; Leung JC; Chan LY; Lam CW; Chan IH; Chan HW; Li CS; Wong SS; Ho YW; Cheuk A; Tong MK; Tang SC
Perit Dial Int; 2012; 32(3):280-91. PubMed ID: 22045098
[TBL] [Abstract][Full Text] [Related]
2. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
3. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
4. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
5. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
6. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal dialysis solutions low in glucose degradation products--evidence for clinical benefits.
Tomo T
Perit Dial Int; 2008 Jun; 28 Suppl 3():S123-7. PubMed ID: 18552241
[TBL] [Abstract][Full Text] [Related]
8. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.
Yung S; Lui SL; Ng CK; Yim A; Ma MK; Lo KY; Chow CC; Chu KH; Chak WL; Lam MF; Yung CY; Yip TP; Wong S; Tang CS; Ng FS; Chan TM
Perit Dial Int; 2015; 35(2):147-58. PubMed ID: 25904773
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
10. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
11. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
12. A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation.
le Poole CY; Welten AG; ter Wee PM; Paauw NJ; Djorai AN; Valentijn RM; Beelen RH; van den Born J; van Ittersum FJ
Perit Dial Int; 2012; 32(3):305-15. PubMed ID: 22045100
[TBL] [Abstract][Full Text] [Related]
13. A new neutral-pH low-GDP peritoneal dialysis fluid.
Himmele R; Jensen L; Fenn D; Ho CH; Sawin DA; Diaz-Buxo JA
Perit Dial Int; 2012; 32(4):444-52. PubMed ID: 22383632
[TBL] [Abstract][Full Text] [Related]
14. Icodextrin and intraperitoneal inflammation.
Moriishi M; Kawanishi H
Perit Dial Int; 2008 Jun; 28 Suppl 3():S96-S100. PubMed ID: 18552274
[TBL] [Abstract][Full Text] [Related]
15. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
16. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
17. Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells.
Fernández-Perpén A; Pérez-Lozano ML; Bajo MA; Albar-Vizcaino P; Sandoval Correa P; del Peso G; Castro MJ; Aguilera A; Ossorio M; Peter ME; Passlick-Deetjen J; Aroeira LS; Selgas R; López-Cabrera M; Sánchez-Tomero JA
Perit Dial Int; 2012; 32(3):292-304. PubMed ID: 22215656
[TBL] [Abstract][Full Text] [Related]
18. The effects of peritoneal dialysis solutions on peritoneal host defense.
Mortier S; Lameire NH; De Vriese AS
Perit Dial Int; 2004; 24(2):123-38. PubMed ID: 15119633
[TBL] [Abstract][Full Text] [Related]
19. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
Johnson DW; Clarke M; Wilson V; Woods F; Brown FG
BMC Nephrol; 2010 Sep; 11():25. PubMed ID: 20843375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
